 Idera Pharmaceuticals Inc NASDAQ: IDRA shared positive interim results from its investigator-sponsored Phase 2 trial, INTRIM 1, involving tilsotolimod, Ideras synthetic Toll-like receptor 9 agonist. Based on these results, the trial has been stopped early. 